555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [cầu bach thủ]
The primary objective is complete response (CR) after treatment with investigational agent initiated by ctDNA positive status after radical cystectomy (with or without concomitant visible …
Sep 18, 2024 · At ESMO 2024, Amanda Nizam, MD, from the Cleveland Clinic and Jørgen Bjerggaard Jensen, MD, from Aarhus University discuss the TOMBOLA trial, assessing early …
Feb 13, 2023 · The data revealed that the likelihood of achieving a pathologic complete response (pCR) was significantly higher for patients found to be ctDNA negative prior to NAC or …
Jørgen Bjerggaard Jensen presented the preliminary results from the TOMBOLA trial, which evaluated whether serial circulating tumour DNA (ctDNA) testing could be used to identify …
Sep 16, 2024 · Preliminary findings from the TOMBOLA trial presented at the European Society for Medical Oncology Congress 2024 indicate that circulating tumor DNA (ctDNA) testing could …
Sep 15, 2024 · Early results show ctDNA’s high specificity in identifying those at risk for metastases, potentially enabling personalized, timely intervention with immunotherapy. This …
The TOMBOLA trial is an ongoing national, multicentre, non-randomized, interventional study in Denmark where patients undergoing NAC and RC because of non-metastatic MIBC (cT2 …
Sep 18, 2024 · At ESMO 2024, Amanda Nizam, MD, from the Cleveland Clinic and Jørgen Bjerggaard Jensen, MD, from Aarhus University discuss the TOMBOLA trial, assessing early …
Apr 25, 2025 · In this study, we investigated the use of circulating tumor DNA (ctDNA) to guide immunotherapy after cystectomy (TOMBOLA trial; NCT04138628).
The TOMBOLA study aims to investigate the potential benefits of ctDNA-guided administration of adjuvant immunotherapy following radical cystectomy in patients diagnosed with locally …
Bài viết được đề xuất: